1Shon T, Nishizawa Y, Toyaka A, et al. Treatment with pravastatin of dyslipidemia associated with diabetic nephropathy [ J ].Nephrol, 1991,59 (5) : 664.
2Tonolo G, Ciccarse M, Brizzi P, et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long - term simvastatin treatment [ J ]. Diabetes Care, 1997, 20(10) : 1891.
3Kamei N ,Tobe K, Suzuki R, et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance[ J], J Biol Chem,2006,281 (36) : 26602 - 14,
4Lee S, Kim B, Sik Y, et al. Hight glucose induces MCP-1 expression partly via tyrosine kinase-AP-1 pathway in peritoneal mesothelial cells[ J]. Kidney Int,2001,60( 1 ) :55 -64.
5Ehlermann P, Eggers K, Bierhaus A, et al. Increased proinflamma- toryendothelial response to S100AS/A9 after preactivation through advanced glycation end products [ J ]. Cardiovasc diabetol, 2006,5 (6):1 -9.
6Ceriello A, Quagliaro L, Piconi L, et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment [ J ]. Diabetes,2004,53 (3) :701 - 10.
7Ortego M, Gamez-Hemandez A, Vidal C, et al. HMG-CoA reductase inhibitors reduce Ⅰ kappa B kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells [ J ]. J Cardiovase Pharmacol,2005,45 ( 5 ) :468 - 75.
8Han K H,Ryu J,Hong K H,et al. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo [ J ]. Circulation ,2005,111 ( 11 ) : 1439 - 47.
